Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in renal transplant recipient

被引:23
作者
Bienvenu, B
Thervet, E
Bedrossian, J
Scieux, C
Mazeron, MC
Thouvenot, D
Legendre, C
机构
[1] Hop St Louis, Serv Nephrol, F-75475 Paris 10, France
[2] Hop St Louis, Serv Virol, F-75475 Paris, France
[3] Hop Lariboisiere, Serv Virol, F-75475 Paris, France
[4] Serv Virol, Lyon, France
关键词
D O I
10.1097/00007890-200001150-00032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The emergence of a resistant strain is a theoretical threat after extensive use of antiviral drugs, We report the emergence of a ganciclovir-resistant cytomegalovirus (CMV) strain in a kidney transplant recipient during oral ganciclovir maintenance treatment. The patient was treated by oral ganciclovir for 2 months after successful treatment of CMV primary infection by intravenous ganciclovir, He developed a ne cv episode of CMV infection with no clinical response to intravenous ganciclovir, The CMV isolate exhibited both phenotypic and genotypic resistance to ganciclovir, The CMV isolate was constituted of a mixture of strains, with and without a mutation at codon 460 of the UL97 gene. The clinical condition improved when mycophenolate mofetil (MMF) was discontinued, and a short course of intravenous globulin was added to ganciclovir, The emergence of the CMV strain could be secondary to more potent immunosuppression provide by MMF or subtherapeutic level obtained during oral ganciclovir treatment. We believe that ganciclovir resistance must be part of the differential diagnosis when a patient relapses or fails to respond to ganciclovir treatment.
引用
收藏
页码:182 / 184
页数:3
相关论文
共 12 条
[1]   Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient [J].
Alain, S ;
Honderlick, P ;
Grenet, D ;
Stern, M ;
Vadam, C ;
SansonLePors, MJ ;
Mazeron, MC .
TRANSPLANTATION, 1997, 63 (10) :1533-1536
[2]   GANCICLOVIR ABSOLUTE BIOAVAILABILITY AND STEADY-STATE PHARMACOKINETICS AFTER ORAL-ADMINISTRATION OF 2 3000-MG/D DOSING REGIMENS IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE AND CYTOMEGALOVIRUS-SEROPOSITIVE PATIENTS [J].
ANDERSON, RD ;
GRIFFY, KG ;
JUNG, D ;
DORR, A ;
HULSE, JD ;
SMITH, RB .
CLINICAL THERAPEUTICS, 1995, 17 (03) :425-432
[3]   Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood [J].
Baldanti, F ;
Simoncini, L ;
Sarasini, A ;
Zavattoni, M ;
Grossi, P ;
Revell, MG ;
Gerna, G .
TRANSPLANTATION, 1998, 66 (03) :324-329
[4]   USE OF AN ENZYME-LINKED IMMUNOSORBENT-ASSAY PERFORMED DIRECTLY ON FIXED INFECTED CELL MONOLAYERS FOR EVALUATING DRUGS AGAINST VARICELLA-ZOSTER VIRUS [J].
BERKOWITZ, FE ;
LEVIN, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (02) :207-210
[5]   Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis [J].
Bowen, EF ;
Emery, VC ;
Wilson, P ;
Johnson, MA ;
Davey, CC ;
Sabin, CA ;
Farmer, D ;
Griffiths, PD .
AIDS, 1998, 12 (06) :605-611
[6]   Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients [J].
Brennan, DC ;
Garlock, KA ;
Singer, GG ;
Schnitzler, MA ;
Lippmann, BJ ;
Buller, RS ;
Gaudreault-Keener, M ;
Lowell, JA ;
Shenoy, S ;
Howard, TK ;
Storch, GA .
TRANSPLANTATION, 1997, 64 (12) :1843-1846
[7]   ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE [J].
CHOU, SW ;
ERICE, A ;
JORDAN, MC ;
VERCELLOTTI, GM ;
MICHELS, KR ;
TALARICO, CL ;
STANAT, SC ;
BIRON, KK .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :576-583
[8]   Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients [J].
Gane, E ;
Saliba, F ;
Valdecasas, GJC ;
OGrady, J ;
Pescovitz, MD ;
Lyman, S ;
Robinson, CA .
LANCET, 1997, 350 (9093) :1729-1733
[9]   NOVEL MUTATION IN THE UL97 GENE OF A CLINICAL CYTOMEGALOVIRUS STRAIN CONFERRING RESISTANCE TO GANCICLOVIR [J].
HANSON, MN ;
PREHEIM, LC ;
CHOU, SW ;
TALARICO, CL ;
BIRON, KK ;
ERICE, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1204-1205
[10]   Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation [J].
Lowance, D ;
Neumayer, HH ;
Legendre, CM ;
Squifflet, JP ;
Kovarik, J ;
Brennan, PJ ;
Norman, D ;
Mendez, R ;
Keating, MR ;
Coggon, GL ;
Crisp, A ;
Lee, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (19) :1462-1470